Cost of Revenue Comparison: Neurocrine Biosciences, Inc. vs Galapagos NV

Biotech Giants' Cost of Revenue: A Decade of Change

__timestampGalapagos NVNeurocrine Biosciences, Inc.
Wednesday, January 1, 201411111000014400000
Thursday, January 1, 201512971400033800000
Friday, January 1, 201613957400035900000
Sunday, January 1, 20172185020001254000
Monday, January 1, 20183228760004889000
Tuesday, January 1, 20194273200007400000
Wednesday, January 1, 202052366700010100000
Friday, January 1, 2021162900014300000
Saturday, January 1, 20221207900023200000
Sunday, January 1, 20233598900039700000
Monday, January 1, 202434000000
Loading chart...

Infusing magic into the data realm

Cost of Revenue: A Tale of Two Biotech Giants

In the competitive world of biotechnology, cost management is crucial for success. This chart compares the cost of revenue for Neurocrine Biosciences, Inc. and Galapagos NV from 2014 to 2023. Over this period, Galapagos NV experienced a significant increase in cost of revenue, peaking in 2020 with a staggering 370% rise from 2014. In contrast, Neurocrine Biosciences, Inc. maintained a more stable trajectory, with costs increasing by approximately 175% over the same period. Notably, 2021 marked a dramatic drop for Galapagos NV, with costs plummeting to just 1% of their 2020 peak. This fluctuation highlights the volatile nature of the biotech industry, where strategic decisions and market conditions can dramatically impact financial outcomes. As we look to the future, these trends offer valuable insights into the financial strategies of these two industry leaders.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025